Gainers

• NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million.
• Intensity Therapeutics (NASDAQ:INTS) stock rose 9.58% to $3.66. The company's market cap stands at $10.9 million.
• iSpecimen (NASDAQ:ISPC) shares moved upwards by 9.42% to $0.87. The company's market cap stands at $1.9 million.
• Entera Bio (NASDAQ:ENTX) shares moved upwards by 9.29% to $3.41. The company's market cap stands at $542.6 million.
• Clearmind Medicine (NASDAQ:CMND) stock rose 8.54% to $6.35. The company's market cap stands at $2.9 million.
• Psyence Biomedical (NASDAQ:PBM) stock increased by 8.5% to $3.92. The company's market cap stands at $13.7 million.

Losers

• Acumen Pharmaceuticals (NASDAQ:ABOS) shares decreased by 77.5% to $0.51 during Friday's pre-market session. The company's market cap stands at $165.6 million. As per the press release, Q3 earnings came out 4 days ago.
• Alphatec Holdings (NASDAQ:ATEC) stock fell 31.93% to $7.74. The market value of their outstanding shares is at $1.7 billion. As per the news, the Q3 earnings report came out yesterday.
• ProMIS Neurosciences (NASDAQ:PMN) shares fell 24.1% to $8.41. The company's market cap stands at $99.3 million.
• Senti Biosciences (NASDAQ:SNTI) shares decreased by 18.35% to $0.18. The company's market cap stands at $8.3 million.
• OmniAb (NASDAQ:OABI) stock fell 16.07% to $4.39. The company's market cap stands at $758.2 million. As per the press release, Q3 earnings came out today.
• Davion Healthcare (NASDAQ:DAVI) shares declined by 14.13% to $2.31. The company's market cap stands at $67.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.